查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1764118

隱球菌病治療市場－全球產業規模、佔有率、趨勢、機會和預測（按治療、配銷通路、地區和競爭細分，2020-2030 年）

Cryptococcosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球隱球菌病治療市場規模為53.4億美元，預計2030年將達到72.8億美元，預測期內的複合年成長率為5.27%。隱球菌病主要影響肺部和中樞神經系統，其原因是吸入受鳥糞污染的土壤中常見的真菌孢子。免疫抑制性疾病（如愛滋病毒/愛滋病、器官移植和癌症治療）的發生率不斷上升，顯著增加了感染的可能性。因此，對抗真菌治療的需求正在成長。先進療法、改進的藥物配方和聯合療法的持續研究進一步支持了市場成長。製藥公司、研究機構和公共衛生實體之間的策略合作有助於推動創新和擴大有效療法的可及性，最終提高存活率和患者預後。

市場概覽
預測期 2026-2030
2024年市場規模 53.4億美元
2030年市場規模 72.8億美元
2025-2030 年複合年成長率 5.27%
成長最快的領域 氟胞嘧啶
最大的市場 北美洲

關鍵市場促進因素

免疫缺陷症盛行率不斷上升

主要市場挑戰

真菌感染的複雜性

主要市場趨勢

技術進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球隱球菌病治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療方法（兩性黴素 B、氟胞嘧啶、氟康唑等）
    • 按配銷通路（醫院、零售藥局、專科診所、其他）
    • 按地區
    • 按公司分類（前五大市場參與者的股份）
  • 市場地圖
    • 按治療
    • 按配銷通路
    • 按地區

第6章：北美隱球菌病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第7章：歐洲隱球菌病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第8章：亞太地區隱球菌病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第9章：南美隱球菌病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 10 章：中東和非洲隱球菌病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 治療啟動

第 13 章：競爭格局

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

第 14 章：策略建議

第15章調查會社について,免責事項

簡介目錄
Product Code: 15909

The Global Cryptococcosis Therapeutics Market was valued at USD 5.34 billion in 2024 and is anticipated to reach USD 7.28 billion by 2030, growing at a CAGR of 5.27% during the forecast period. Cryptococcosis, primarily affecting the lungs and central nervous system, arises from the inhalation of fungal spores commonly found in soil contaminated by bird droppings. The rising incidence of immunosuppressive conditions-such as HIV/AIDS, organ transplantation, and cancer therapies-has significantly increased the susceptibility to this infection. Consequently, demand for antifungal treatments is rising. Market growth is further supported by ongoing research into advanced therapies, improved drug formulations, and combination treatments. Strategic collaborations among pharmaceutical companies, research institutions, and public health entities are instrumental in driving innovation and expanding access to effective therapies, ultimately improving survival rates and patient outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.34 Billion
Market Size 2030USD 7.28 Billion
CAGR 2025-20305.27%
Fastest Growing SegmentFlucytosine
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Immunocompromised Conditions

The growing number of individuals with compromised immune systems has become a significant driver of the cryptococcosis therapeutics market. HIV/AIDS continues to be a major risk factor, particularly in low-resource settings with limited access to antiretroviral therapy. According to UNAIDS, nearly 39 million individuals were living with HIV globally in 2023. This group remains highly susceptible to opportunistic infections like cryptococcosis. Additionally, advances in medical procedures such as organ transplantation are contributing to the expanding immunosuppressed population. Over 157,000 solid organ transplants were conducted globally in 2022, with recipients requiring lifelong immunosuppressive therapy-thereby increasing their risk of fungal infections. As this vulnerable demographic grows, the need for effective antifungal therapies becomes increasingly urgent.

Key Market Challenges

Complexity of Fungal Infections

Cryptococcosis presents inherent treatment challenges due to the complex biology of fungal pathogens. Unlike bacteria, fungi share many cellular features with human cells, limiting drug targets and raising concerns over toxicity. Cryptococcus neoformans, the causative agent, possesses defense mechanisms such as robust cell walls, protective capsules, and biofilm formation that hinder treatment efficacy. Antifungal resistance, limited therapeutic options, and poor diagnostic capabilities-especially in resource-limited settings-further complicate management. Current treatments, including amphotericin B and flucytosine, often require intravenous administration and are associated with considerable side effects. Treating cryptococcal meningitis is particularly challenging due to the blood-brain barrier, which restricts drug penetration. These barriers not only impact clinical outcomes but also discourage pharmaceutical innovation due to high development costs and regulatory hurdles.

Key Market Trends

Technological Advancements

Technological progress is shaping the future of the cryptococcosis therapeutics market by enhancing diagnostic accuracy and therapeutic delivery. Advanced molecular diagnostic tools like PCR assays and next-generation sequencing are improving early detection and guiding timely intervention. Point-of-care diagnostic kits are also gaining traction, particularly in low-resource areas. In treatment, innovations such as liposomal formulations of amphotericin B are reducing toxicity while maintaining efficacy. Nanotechnology and targeted delivery systems are being explored to enhance drug bioavailability and CNS penetration. Moreover, artificial intelligence and bioinformatics are accelerating antifungal drug discovery. These developments are addressing long-standing therapeutic gaps and laying the foundation for personalized treatment strategies in managing cryptococcal infections.

Key Market Players

  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals
  • Janssen Biotech Inc. (Johnson & Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc
  • Asahi Kasei Pharma
  • Sigmapharm Laboratories LLC

Report Scope:

In this report, the Global Cryptococcosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cryptococcosis Therapeutics Market, By Treatment:

  • Amphotericin B
  • Flucytosine
  • Fluconazole
  • Other

Cryptococcosis Therapeutics Market, By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Specialty Clinics
  • Others

Cryptococcosis Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cryptococcosis Therapeutics Market.

Available Customizations:

Global Cryptococcosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cryptococcosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Amphotericin B, Flucytosine, Fluconazole, Others)
    • 5.2.2. By Distribution Channel (Hospitals, Retail Pharmacies, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Cryptococcosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
      • 6.2.3.1. United States Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.1.1. Market Size & Forecast
          • 6.2.3.1.1.1. By Value
        • 6.2.3.1.2. Market Share & Forecast
          • 6.2.3.1.2.1. By Treatment
          • 6.2.3.1.2.2. By Distribution Channel
      • 6.2.3.2. Canada Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.2.1. Market Size & Forecast
          • 6.2.3.2.1.1. By Value
        • 6.2.3.2.2. Market Share & Forecast
          • 6.2.3.2.2.1. By Treatment
          • 6.2.3.2.2.2. By Distribution Channel
      • 6.2.3.3. Mexico Cryptococcosis Therapeutics Market Outlook
        • 6.2.3.3.1. Market Size & Forecast
          • 6.2.3.3.1.1. By Value
        • 6.2.3.3.2. Market Share & Forecast
          • 6.2.3.3.2.1. By Treatment
          • 6.2.3.3.2.2. By Distribution Channel

7. Europe Cryptococcosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. France Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.1.1. Market Size & Forecast
          • 7.2.3.1.1.1. By Value
        • 7.2.3.1.2. Market Share & Forecast
          • 7.2.3.1.2.1. By Treatment
          • 7.2.3.1.2.2. By Distribution Channel
      • 7.2.3.2. Germany Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.2.1. Market Size & Forecast
          • 7.2.3.2.1.1. By Value
        • 7.2.3.2.2. Market Share & Forecast
          • 7.2.3.2.2.1. By Treatment
          • 7.2.3.2.2.2. By Distribution Channel
      • 7.2.3.3. United Kingdom Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.3.1. Market Size & Forecast
          • 7.2.3.3.1.1. By Value
        • 7.2.3.3.2. Market Share & Forecast
          • 7.2.3.3.2.1. By Treatment
          • 7.2.3.3.2.2. By Distribution Channel
      • 7.2.3.4. Italy Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.4.1. Market Size & Forecast
          • 7.2.3.4.1.1. By Value
        • 7.2.3.4.2. Market Share & Forecast
          • 7.2.3.4.2.1. By Treatment
          • 7.2.3.4.2.2. By Distribution Channel
      • 7.2.3.5. Spain Cryptococcosis Therapeutics Market Outlook
        • 7.2.3.5.1. Market Size & Forecast
          • 7.2.3.5.1.1. By Value
        • 7.2.3.5.2. Market Share & Forecast
          • 7.2.3.5.2.1. By Treatment
          • 7.2.3.5.2.2. By Distribution Channel

8. Asia Pacific Cryptococcosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
      • 8.2.3.1. China Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.1.1. Market Size & Forecast
          • 8.2.3.1.1.1. By Value
        • 8.2.3.1.2. Market Share & Forecast
          • 8.2.3.1.2.1. By Treatment
          • 8.2.3.1.2.2. By Distribution Channel
      • 8.2.3.2. India Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.2.1. Market Size & Forecast
          • 8.2.3.2.1.1. By Value
        • 8.2.3.2.2. Market Share & Forecast
          • 8.2.3.2.2.1. By Treatment
          • 8.2.3.2.2.2. By Distribution Channel
      • 8.2.3.3. South Korea Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.3.1. Market Size & Forecast
          • 8.2.3.3.1.1. By Value
        • 8.2.3.3.2. Market Share & Forecast
          • 8.2.3.3.2.1. By Treatment
          • 8.2.3.3.2.2. By Distribution Channel
      • 8.2.3.4. Japan Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.4.1. Market Size & Forecast
          • 8.2.3.4.1.1. By Value
        • 8.2.3.4.2. Market Share & Forecast
          • 8.2.3.4.2.1. By Treatment
          • 8.2.3.4.2.2. By Distribution Channel
      • 8.2.3.5. Australia Cryptococcosis Therapeutics Market Outlook
        • 8.2.3.5.1. Market Size & Forecast
          • 8.2.3.5.1.1. By Value
        • 8.2.3.5.2. Market Share & Forecast
          • 8.2.3.5.2.1. By Treatment
          • 8.2.3.5.2.2. By Distribution Channel

9. South America Cryptococcosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
      • 9.2.3.1. Brazil Cryptococcosis Therapeutics Market Outlook
        • 9.2.3.1.1. Market Size & Forecast
          • 9.2.3.1.1.1. By Value
        • 9.2.3.1.2. Market Share & Forecast
          • 9.2.3.1.2.1. By Treatment
          • 9.2.3.1.2.2. By Distribution Channel
      • 9.2.3.2. Argentina Cryptococcosis Therapeutics Market Outlook
        • 9.2.3.2.1. Market Size & Forecast
          • 9.2.3.2.1.1. By Value
        • 9.2.3.2.2. Market Share & Forecast
          • 9.2.3.2.2.1. By Treatment
          • 9.2.3.2.2.2. By Distribution Channel
      • 9.2.3.3. Colombia Cryptococcosis Therapeutics Market Outlook
        • 9.2.3.3.1. Market Size & Forecast
          • 9.2.3.3.1.1. By Value
        • 9.2.3.3.2. Market Share & Forecast
          • 9.2.3.3.2.1. By Treatment
          • 9.2.3.3.2.2. By Distribution Channel

10. Middle East & Africa Cryptococcosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
      • 10.2.3.1. South Africa Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.1.1. Market Size & Forecast
          • 10.2.3.1.1.1. By Value
        • 10.2.3.1.2. Market Share & Forecast
          • 10.2.3.1.2.1. By Treatment
          • 10.2.3.1.2.2. By Distribution Channel
      • 10.2.3.2. Saudi Arabia Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.2.1. Market Size & Forecast
          • 10.2.3.2.1.1. By Value
        • 10.2.3.2.2. Market Share & Forecast
          • 10.2.3.2.2.1. By Treatment
          • 10.2.3.2.2.2. By Distribution Channel
      • 10.2.3.3. UAE Cryptococcosis Therapeutics Market Outlook
        • 10.2.3.3.1. Market Size & Forecast
          • 10.2.3.3.1.1. By Value
        • 10.2.3.3.2. Market Share & Forecast
          • 10.2.3.3.2.1. By Treatment
          • 10.2.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Treatment Launches

13. Competitive Landscape

  • 13.1. Astellas Pharma Inc
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. Bristol-Myers Squibb Company
  • 13.3. Glenmark Pharmaceuticals
  • 13.4. Janssen Biotech Inc.( Johnson & Johnson Services, Inc.)
  • 13.5. Novartis AG
  • 13.6. Pfizer Inc
  • 13.7. Asahi Kasei Pharma
  • 13.8. Sigmapharm Laboratories LLC

14. Strategic Recommendations

15. About us & Disclaimer